XML 65 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Notes Payable (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
May 31, 2021
Jan. 31, 2021
May 31, 2020
Apr. 30, 2019
Feb. 28, 2019
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
2019 MD Loan [Member]                      
Notes Payable (Details) [Line Items]                      
Term loan         $ 500            
Interest rate         8.00%            
Outstanding due date         Feb. 22, 2034            
Phantom shares, description         The 2019 MD Loan establishes “Phantom Shares,” based on 119,906 shares of Common Stock (based on 863,110 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance.            
Interest income           $ 500     $ 300    
Interest expense             $ 200     $ 300  
Fair value of long-term notes payable           800     800   $ 1,100
2019 Cecil Loan [Member]                      
Notes Payable (Details) [Line Items]                      
Term loan       $ 100              
Interest rate       8.00%              
Outstanding due date       Apr. 30, 2034              
Phantom shares, description       The 2019 Cecil Loan establishes “Phantom Shares,” based on 23,981 shares of Common Stock (based on 172,622 Series C Preferred Shares prior to the Reverse Recapitalization), determined at issuance.              
Interest expense           9 $ 42   52 $ 55  
Fair value of long-term notes payable           200     200   $ 200
Amount of income           100          
PPP Note [Member]                      
Notes Payable (Details) [Line Items]                      
Note payable     $ 600                
Percentage of loan amount used for payroll expenses     60.00%                
Debt extinguishment   $ 600                  
2021 Avenue Loan [Member] | Tranche one [Member]                      
Notes Payable (Details) [Line Items]                      
First loan amount $ 20,000                    
Funded amount 15,000                    
Unfunded amount 5,000                    
2021 Avenue Loan [Member] | Tranche Two [Member]                      
Notes Payable (Details) [Line Items]                      
Second loan amount 10,000                    
2021 Avenue Loan [Member] | Notes Payable [Member]                      
Notes Payable (Details) [Line Items]                      
Term loan 30,000                    
Interest expense           600     800    
Accrued debt issuance costs 500               75    
Amortization of Debt Issuance Costs $ 35                    
Conditions for future funding, description funding of Tranche 2 is subject to evidence reasonably satisfactory to Avenue of receipt of an additional $5.0 million financing through Maryland’s State Incentive Programs and/or other Maryland State programs and mutual agreement of the Company and Avenue. On September 27, 2021, we obtained a waiver from this additional financing requirement for the funding of the remaining $5.0 million of Tranche 1 and exercised the option to postpone principal repayment by one year. We incurred additional issuance costs of $75 thousand upon funding the remaining $5.0 million of Tranche 1, of which $12 thousand has been expensed immediately. Funding of Tranche 2 is also subject to (a) our achievement of a statistically significant result on the primary endpoint as defined within the statistical analysis plan for each respective study, or the totality of the results for any study warrant advancement into a subsequent clinical efficacy study, as reasonably determined by the Company and Avenue with respect to at least two of the following studies: (i) RESCUE-ALS or the Healey ALS Platform Trial; (ii) REPAIR-PD; or (iii) REPAIR-MS (“Performance Milestone 1”); and (b) our receipt of net proceeds of at least $30 million from the sale and issuance of our equity securities (including any private placement or follow-on offering) between May 2, 2021 and June 30, 2022.                    
Debt issuance costs                 $ 12    
Rate of interest, description                 The loans bear interest at a variable rate per annum equal to the sum of (i) the greater of (A) the prime rate, as published by the Wall Street Journal from time to time or (B) 3.25%, plus (ii) 6.60%. Payments for the loan are interest only for the initial 12 months and can be extended to (i) 12 months (the “First Interest-only Period Extension”) if we achieve Performance Milestone 1 and (ii) up to 36 months if (a) we achieve the First Interest-only Period Extension and (b) have drawn from Tranche 2. On August 16, 2021, we mutually confirmed with Avenue that Performance Milestone 1 and the First Interest-only Period Extension had been achieved.    
Additional payment upon maturity, description               On the maturity date, an additional payment equal to 4.25% of the funded loans, or $0.6 million, is due in addition to the remaining unpaid principal and accrued interest.      
Warrant to purchase shares (in Shares) 115,851                    
Common stock at an exercise price (in Dollars per share) $ 8.63                    
Tranche warrant adjustment description Upon the funding of Tranche 2, the Avenue Warrant shall be automatically adjusted to include an additional estimated 86,679 shares of Common Stock, which is equal to 5% of the principal amount of Tranche 2, divided by the lower of (i) the five (5)-day VWAP per share; determined as of the end of trading on the last trading day before the date of issuance of Tranche 2; or (ii) the Next Round Price.                    
Convertible note payable $ 5,000                    
Conversion percentage of common stock price for convertible note payable, percentage 120.00%                    
Trading volume limit for conversion of convertible note payable, percentage 20.00%                    
Threshold for removal of financial covenants, description                 The financial covenant associated with the loan agreement includes maintaining minimum unrestricted cash and cash equivalents of at least $5.0 million; provided that upon our (i) achievement of Performance Milestone 1, and (ii) receiving of net proceeds of at least $30.0 million from the sale and issuance of our equity securities (including any PIPE or follow-on offering) between May 1, 2021 and June 30, 2022, we shall no longer be subject to financial covenants.    
Minimum cash balance for loan covenant                 $ 5,000    
Fair value of warrant $ 1,000                    
Financing costs $ 500                    
Convertible debt           $ 5,000     $ 5,000